Skip to main content

NASDAQ:DCTH - Delcath Systems Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $22.75
  • Forecasted Upside: 123.04 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$10.20
▲ +0.46 (4.72%)
1 month | 3 months | 12 months
Get New Delcath Systems Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DCTH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DCTH

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$22.75
▲ +123.04% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Delcath Systems in the last 3 months. The average price target is $22.75, with a high forecast of $25.00 and a low forecast of $19.00. The average price target represents a 123.04% upside from the last price of $10.20.

Buy

The current consensus among 4 contributing investment analysts is to buy stock in Delcath Systems.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/21/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/19/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/17/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/15/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/16/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2021BTIG ResearchReiterated RatingBuy$23.00Low
i
Rating by Marie Thibault at BTIG Research
4/13/2021Roth CapitalBoost Price TargetBuy$20.00 ➝ $25.00N/A
i
4/6/2021Roth CapitalBoost Price TargetBuy$20.00 ➝ $25.00Medium
i
3/15/2021Canaccord GenuityInitiated CoverageBuy$24.00N/A
i
3/9/2021Canaccord GenuityInitiated CoverageBuy$24.00High
i
1/5/2021BTIG ResearchInitiated CoverageBuy$23.00N/A
i
1/4/2021BTIG ResearchInitiated CoverageBuy$23.00N/A
i
6/4/2020Roth CapitalReiterated RatingBuyLow
i
Rating by S. Henry at Roth Capital
6/4/2020Roth CapitalInitiated CoverageBuy$20.00High
i
6/1/2020LaidlawInitiated CoverageBuy$19.00High
i
(Data available from 5/16/2016 forward)
Delcath Systems logo
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma; and the ALIGN trial, a Phase 3 clinical trial for intrahepatic cholangiocarcinoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Read More

Today's Range

Now: $10.20
$9.53
$10.39

50 Day Range

MA: $12.59
$9.54
$16.89

52 Week Range

Now: $10.20
$7.15
$25.18

Volume

67,237 shs

Average Volume

229,174 shs

Market Capitalization

$66.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Frequently Asked Questions

What sell-side analysts currently cover shares of Delcath Systems?

The following equities research analysts have issued research reports on Delcath Systems in the last twelve months: BTIG Research, Canaccord Genuity, Laidlaw, Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for DCTH.

What is the current price target for Delcath Systems?

4 Wall Street analysts have set twelve-month price targets for Delcath Systems in the last year. Their average twelve-month price target is $22.75, suggesting a possible upside of 123.0%. Roth Capital has the highest price target set, predicting DCTH will reach $25.00 in the next twelve months. Laidlaw has the lowest price target set, forecasting a price of $19.00 for Delcath Systems in the next year.
View the latest price targets for DCTH.

What is the current consensus analyst rating for Delcath Systems?

Delcath Systems currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DCTH will outperform the market and that investors should add to their positions of Delcath Systems.
View the latest ratings for DCTH.

What other companies compete with Delcath Systems?

How do I contact Delcath Systems' investor relations team?

Delcath Systems' physical mailing address is 1633 BROADWAY SUITE 22C, NEW YORK NY, 10019. The company's listed phone number is 212 489 2100 and its investor relations email address is [email protected] The official website for Delcath Systems is delcath.com.